![Mark Ginski](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mark Ginski
Corporate Officer/Principal en VISTAGEN THERAPEUTICS, INC. .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Jon Saxe | M | 88 | 24 años | |
Maggie FitzPatrick | F | 58 | 3 años | |
Ann Cunningham | F | 56 | 5 años | |
Shawn Singh | M | 61 | 24 años | |
Jerry Gin | M | 81 | 8 años | |
Mark McPartland | M | 58 | 8 años | |
Mark Flather | M | - | 3 años | |
Joanne Curley | M | 56 | 3 años | |
Mary Rotunno | F | 64 | 3 años | |
Ross Baker | M | - | 3 años | |
Jessica Haskell | F | - | 2 años | |
Allen Cato | M | - | - | |
Reid Adler | M | 70 | 2 años | |
Louis Monti | M | - | 4 años | |
Erik Berglund | M | - | 3 años | |
Trisha Fitzmaurice | F | - | 2 años | |
Joshua Prince | M | 54 | 3 años | |
Cynthia Anderson | F | 55 | 1 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Bruce Peacock | M | 72 |
Alba Therapeutics Corp.
![]() Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | - |
Wendy Perrow | F | 66 |
Alba Therapeutics Corp.
![]() Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | 8 años |
H. Ralph Snodgrass | M | 74 | 24 años | |
Jeffrey Church | M | 67 |
Alba Therapeutics Corp.
![]() Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | 3 años |
Brian Underdown | M | 83 | 12 años | |
Jerrold Dotson | M | 71 | 12 años | |
Francisco Leon | M | 52 |
Alba Therapeutics Corp.
![]() Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | 3 años |
Mark A. Smith | M | 68 | 6 años | |
Jaakko Lappalainen | M | - | - | |
Ellis Wilson | M | - | 1 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 28 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Mark Ginski
- Red Personal